Instrument Inactif

Gouvernance Cell Therapeutics Inc Nasdaq

US1509346029

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

26/06/23	Sobi finalise l'acquisition de CTI BioPharma pour 1,7 milliard de dollars	MT
26/06/23	En Direct des Marchés : TotalEnergies, Renault, Pernod Ricard, Sanofi, Euronext, Nvidia...

Comité Exécutif: Cell Therapeutics Inc

Dirigeant

Fonctions occupéesDepuis

Henrik Stenqvist

59 ans

Treasurer

Composition du Conseil d'Administration: Cell Therapeutics Inc

Administrateur	ComitésDepuis

Anciens Dirigeants et Administrateurs: Cell Therapeutics Inc

Insider

Fonctions occupées

DepuisJusqu'au

Jim Fong

Chief Operating Officer	01/01/2017	-
Corporate Officer/Principal	01/01/2008	01/07/2023

Michael Metzger

Director/Board Member	20/01/2017	23/06/2023
Independent Dir/Board Member	20/01/2017	23/06/2023

Adam Craig

Director/Board Member	20/03/2017	01/06/2023
Chief Executive Officer	20/03/2017	01/06/2023
Chief Tech/Sci/R&D Officer	-	01/06/2023
President	20/03/2017	01/06/2023

Bruce J. Seeley

Chief Administrative Officer	13/03/2017	26/09/2017
Chief Operating Officer	26/09/2017	10/10/2022
Director of Finance/CFO	13/03/2017	26/09/2017
Corporate Officer/Principal	01/07/2015	13/03/2017
Corporate Secretary	13/03/2017	-

Frederick Telling

Director/Board Member	01/12/2006	13/12/2018
Independent Dir/Board Member	01/12/2006	13/12/2018

Jack W. Singer

Director/Board Member	01/09/1991	02/06/2017
Chief Tech/Sci/R&D Officer	01/09/1991	04/09/2018
Founder	01/09/1991	04/09/2018

Ed Bell

Investor Relations Contact

01/06/2008

01/04/2018

Matthew Plunkett

Corporate Officer/Principal

04/09/2012

22/08/2017

David Parkinson

Director/Board Member	05/06/2017	-
Independent Dir/Board Member	05/06/2017	-

Phillip M. Nudelman

Chairman	01/03/1994	02/06/2017
Independent Dir/Board Member	01/03/1994	02/06/2017

Lou A. Bianco

Chief Administrative Officer	18/08/2010	13/03/2017
Director of Finance/CFO	18/08/2010	13/03/2017
Founder	01/09/1991	13/03/2017
General Counsel	01/09/1991	-
Corporate Secretary	18/08/2010	13/03/2017

James Bianco

Director/Board Member	21/02/2011	14/10/2016
Chief Executive Officer	01/09/1991	02/10/2016
Founder	01/09/1991	14/10/2016
President	01/09/1991	02/10/2016

Monique M. Greer

Investor Relations Contact	12/11/2012	-
Public Communications Contact	12/11/2012	01/10/2016

Mary O'Neil Mundinger

Director/Board Member	01/04/1997	23/09/2016
Independent Dir/Board Member	01/04/1997	23/09/2016

Nancy L. Boman

General Counsel

01/04/2008

01/01/2016

Karen Ignagni

Director/Board Member	03/02/2014	06/11/2015
Independent Dir/Board Member	01/01/1993	06/11/2015

John H. Bauer

Director/Board Member	17/10/2005	20/10/2015
Independent Dir/Board Member	17/10/2005	20/10/2015

Vartan Gregorian

Director/Board Member	01/12/2001	06/03/2014
Independent Dir/Board Member	01/12/2001	06/03/2014

Steven E. Benner

Compliance Officer	13/06/2012	-
Chief Tech/Sci/R&D Officer	14/06/2012	25/06/2013

Daniel G. Eramian

Public Communications Contact

01/03/2006

27/12/2012

Craig Philips

President

01/08/2008

Reed Tuckson

Director/Board Member	01/09/2011	-
Independent Dir/Board Member	01/09/2011	-

Christina A. Waters

Corporate Officer/Principal

18/08/2010

Scott Stromatt

Chief Tech/Sci/R&D Officer	01/01/2004	01/01/2008
General Counsel	01/01/2003	01/01/2008

Richard L. Love

Director/Board Member	01/09/2007	-
Chief Executive Officer	02/10/2016	20/03/2017
Chairman	02/06/2017	26/09/2017
Independent Dir/Board Member	01/09/2007	02/10/2016
Portfolio Manager-Equities	04/03/2010	04/03/2010
President	02/10/2016	20/03/2017

Russell Hawkinson

Comptroller/Controller/Auditor	01/01/2007	01/01/2007
Director of Finance/CFO	01/01/2007	01/01/2007

Mauro G. Premi

Corporate Officer/Principal

01/04/2006

Kenny Crouch

Sales & Marketing

01/12/2005

Alberto Bernareggi

Corporate Officer/Principal

21/09/2005

John Fluke

Director/Board Member

01/01/2002

19/08/2005

Erich Maximilian Platzer

Director/Board Member

19/08/2005

Silvano Spinelli

Corporate Officer/Principal

19/08/2005

Stephen Aselage

Corporate Officer/Principal

01/06/2005

James Canfield

Chief Administrative Officer

01/04/2005

Richard E. Leigh

General Counsel	01/01/2005	01/01/2005
Corporate Secretary	01/01/2005	01/01/2005

Jack L. Bowman

Director/Board Member

01/04/1995

21/05/2004

Edward F. Kenney

Chief Operating Officer

01/01/1999

01/02/2004

Thayer White

Corporate Officer/Principal

01/01/1994

01/01/2004

Bruce R. York

Director of Finance/CFO

01/01/1998

01/01/1999

Warren E. Hall

Corporate Officer/Principal

01/11/1995

01/06/1998

Cynthia Shumate

General Counsel

01/01/1997

01/01/1998

Glenn C. Rice

Director/Board Member

01/01/1993

01/01/1998

William Cadwallader

Sales & Marketing

Jack M. Anthony

Corporate Officer/Principal

George J. Todaro

Corporate Officer/Principal

Martin Sutter

Director/Board Member

Gabriella Pezzoni

Chief Tech/Sci/R&D Officer	22/02/2011	-
Corporate Officer/Principal	-	22/02/2011

Mary G. Bolton

Chief Tech/Sci/R&D Officer

Laura Villa

Public Communications Contact

Athena Countouriotis

Corporate Officer/Principal

Kathleen Fanning

Corporate Officer/Principal

Max E. Link

Chairman

Leah M. Grant

Public Communications Contact

Sy-Shi Wang

Corporate Officer/Principal

Kate M. Whitman

Corporate Officer/Principal

Carolyn M. Paradise

Corporate Officer/Principal

Jeremy Curnock-Cook

Director/Board Member

Gary Acton

Corporate Officer/Principal

Jade R. Brown

Corporate Officer/Principal

Glenn Michelson

Chief Tech/Sci/R&D Officer

Patrick L. Bobbitt

Chief Tech/Sci/R&D Officer

Stewart D. Chipman

Chief Tech/Sci/R&D Officer

17/09/2009

Carol M. Pohlod

Corporate Officer/Principal

Donald W. Wyatt

Corporate Secretary

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	1
Femme	0

Dont comité exécutif

Homme	1
Femme	0

Dont Administrateurs

Homme	0
Femme	0

CTI BioPharma Corp. est une société biopharmaceutique commerciale. Elle se concentre sur l'acquisition, le développement et la commercialisation de thérapies ciblées pour les cancers liés au sang. Son produit commercialement approuvé, VONJO (pacritinib), est un inhibiteur de kinase oral spécifique de JAK2, de la forme mutante de JAK2, d'IRAK1, d'ACVR1 (ALK2) et de FLT3 pour le traitement des patients adultes atteints de myélofibrose primaire ou secondaire (post-polycythémie vera ou post-thrombocytémie essentielle) à risque intermédiaire ou élevé. Elle mène l'étude de phase III PACIFICA sur le pacritinib chez des patients atteints de myélofibrose et de thrombocytopénie sévère dans le cadre d'une exigence de post-commercialisation. Outre la myélofibrose, le profil kinase du pacritinib suggère son utilité thérapeutique potentielle dans des pathologies telles que la leucémie myéloïde aiguë, le syndrome myélodysplasique, la leucémie myélomonocytaire chronique, la maladie du greffon contre l'hôte (GvHD) et la leucémie lymphocytaire chronique (CLL), en raison de son inhibition de JAK2, IRAK1, FLT3, ACVR1 et CSF1R.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société